Navigation Links
Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
Date:1/6/2009

RESEARCH TRIANGLE PARK, N.C., Jan. 6 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that the Company has completed a single and multi-dose Phase I study of CMX001 in healthy volunteers. This study supports the further development of the drug for multiple dsDNA infections. The Company has initiated the first Phase II multi-dose clinical trial in patients.

"The safety and high oral availability demonstrated by CMX001 in the Phase I trial has exceeded our original expectations," said Dr. George Painter, Chimerix President and CEO. "We believe that CMX001 has potential for prevention and treatment of many serious and potentially fatal infections such as smallpox, cytomegalovirus, BK virus and adenovirus."

The Phase I study of CMX001 was a blinded, randomized, placebo-controlled study that evaluated the safety and pharmacokinetics of orally administered CMX001 in healthy volunteers. The study found CMX001 to be well tolerated at all doses in 84 healthy volunteers.

The first Phase II trial will study the effects of multiple doses of CMX001 given to stem cell and kidney transplant recipients with BK viruria, a condition which may eventually lead to loss of the kidney graft, or to uncontrolled bleeding in the bladder. Further studies are planned to explore the ability of CMX001 to prevent cytomegalovirus disease, a viral disease that may lead to blindness or severe gastrointestinal disease after bone marrow transplant.

CMX001 is being developed for the treatment of smallpox infection and other double stranded DNA virus infections that cause significant human morbidity and mortality. A safe, orally active antiviral drug to treat smallpox infection is needed to help people who become ill after exposure to the disease or those who cannot be vaccinated. The work is partially funded by a $36.1 million grant
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
2. Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads
3. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
4. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Carrington Completes $8 Million Financing
7. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
8. New Brunswick Scientific Completes Merger Transaction with Eppendorf
9. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
10. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
11. Optherion, Inc. Completes $37 Million Start Up Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015 Specialty Pharmacy Times has ... admitted to BPA Worldwide as a business publication ... audience data for Specialty Pharmacy Times based on ... becoming a member of BPA Worldwide, Specialty Pharmacy ... clients with the most reliable, unequaled data,” said ...
(Date:5/21/2015)... LONDON , May 21, 2015 ... your inner feelings - and those of others. Being ... and senses. Analyze and read people to anticipate their ... your deepest emotions and feelings to create unique ... generation of responsive games. Get inside a first-person-shooter as ...
(Date:5/21/2015)... , May 20, 2015 Research and Markets ... addition of the "2015 Global Survey on ... offering. The primary goal of this ... cytometry instruments and reagents. Key information the survey ... selection of flow cytometers, predominantly used applications for ...
(Date:5/20/2015)... May 20, 2015 Research and Markets ... "Top Technologies in HW_Technical Insights" report to ... report evaluated technology trends in the Health and Wellness ... likely to have an impact in the year 2015. ... the top 10 health and wellness technologies that are ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2Global Survey on Flow Cytometry Adoption Trends 2015 2Top Technologies in the Health and Wellness Industry 2015 2
... Even HealthierST. LOUIS, March 31 Recent research reveals ... be beneficial to the diet. And, the majority recognizes ... such as soyfoods even healthier. These findings come from ... - sponsored by the United Soybean Board (USB) ...
... Shire plc (LSE: SHP,NASDAQ: SHPGY ), ... agreement with GlaxoSmithKline plc (NYSE: GSK ... aim of,improving recognition and treatment of ADHD in ... and will more than double the reach and,frequency ...
... U.S. FDA approves Intercell,s first marketed product, a new ... - Commercial product launch in the U.S. planned for ... today announced that the U.S. Food and Drug Administration ... of Japanese Encephalitis (JE). The initial target for use ...
Cached Biology Technology:Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 2Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 3Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 2Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 3Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 4Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 5Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 6Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 2Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 3Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 4
(Date:5/19/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
(Date:5/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... of the executive management team will present at the following ... and Telecom Conference Date: May 18, 2015 Time: ... MA Cowen and Company Technology, Media ... Location: The New York Palace Hotel, New York, ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2
... Society applauds the Government of Argentina for creating two ... with majestic shorelines and abundant wildlife. The new ... Marine Parkwere recently established by the National Congress in ... other marine and coastal species., "We commend the Government ...
... This press release is available in German . ... of human infants was investigated using the prominent ,Stanford Marshmallow Experiment,: ... could either eat it now or wait and receive a second ... delay of several minutes. Interestingly, children that were able to wait ...
... study published online today in Nature Communications , researchers ... Sciences, BGI-Shenzhen, and University of Arizona have completed the genome ... provides new insights for researchers to understand the function and ... Oryza is an idea model system for studying plant ...
Cached Biology News:2 new marine protected areas created on Argentina's southern coasts 22 new marine protected areas created on Argentina's southern coasts 3Doing business with a parrot 2Whole genome sequencing of wild rice reveals the mechanisms underlying oryza genome evolution 2